Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch ...

Company Overview - Myriad Genetics is a leader in precision medicine and diagnostic testing, with over 30 years of experience in the field [4] - The company has pioneered BRCA1 testing for breast cancer and has published over 1,000 scientific publications [4] - In 2025, Myriad served over 55,000 healthcare providers and delivered more than 1.5 million test reports [4] Leadership and Vision - The company is led by President and CEO Sam Raha, who emphasizes the noble purpose of advancing health and well-being for all [3][2] - The leadership team is committed to making a significant impact in the healthcare sector [3] Current Position and Future Outlook - Myriad Genetics is at an important inflection point, indicating potential growth and strategic developments ahead [5]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Industry**: Precision medicine and diagnostic testing - **Key Leadership**: Sam Raha (President and CEO), Ben Wheeler (CFO) [1][2] Core Points and Arguments Company Mission and Market Position - Myriad Genetics has a noble purpose to advance health and well-being, being a leader in precision medicine for over 30 years [2] - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025 [3] Strategic Focus - The company is at an inflection point, focusing on the cancer care continuum and expanding its product portfolio beyond hereditary cancer [3][5] - Emphasis on execution excellence, utilizing AI across operations, product development, and customer experience [4][5] Market Opportunities - The total market opportunity for Myriad is estimated at $40 billion, with many served markets growing in double digits and having less than 50% market penetration [6] - Hereditary cancer testing represents a $7 billion market, with Myriad's myRisk test being the gold standard [9][10] Product Development and Launches - Upcoming launches include disease-specific panels for hereditary cancer and an AI-enabled Prolaris test for prostate cancer [10][13] - The company plans to expand its offerings in minimal residual disease (MRD) testing, starting with breast cancer, which has a $7 billion total addressable market (TAM) [19] Financial Performance and Projections - Projected revenue for 2025 is between $822 million and $824 million, with a 6% growth expected for 2026, targeting $860 million to $880 million [28][31] - The company aims to maintain industry-leading gross margins of 68%-69% while reducing costs [31][32] Growth Catalysts - Key growth drivers include the performance of hereditary cancer products, timely launches of new products, and consistent execution of financial and operational goals [38][40] - The company is investing over $35 million to strengthen commercial capabilities related to the cancer care continuum [30][52] Additional Important Content Partnerships and Collaborations - Myriad is exploring strategic partnerships to enhance its market position and product offerings, particularly in the cancer care continuum [45] - Collaborations with Sophia Genetics and MSK are aimed at biomarker selection and companion diagnostic development [12][45] Challenges and Market Dynamics - The prenatal health segment faced a 4% decline in 2025 due to implementation challenges, but recovery efforts are underway [29][30] - Mental health remains a growing area, with the GeneSight test being a market leader, having provided results for over three million patients [26][27] Long-term Vision - Myriad Genetics aims for high-single-digit to low-double-digit revenue growth over the next five years, supported by a robust pipeline of new products and strategic initiatives [33][36] This summary encapsulates the key insights from the Myriad Genetics FY Conference, highlighting the company's strategic direction, market opportunities, financial outlook, and growth initiatives.

Financial Performance and Guidance - Preliminary Q4 2025 total revenue is expected to be between $207 million and $209 million, and full year 2025 revenue between $822 million and $824 million[51] - Total test volume growth for 2025 is approximately 1% year-over-year, with Hereditary Cancer showing 7% growth, Mental Health 6% growth, and Prenatal Health a (4)% decrease[51] - 2026 total revenue guidance is set at $860 million to $880 million, reflecting approximately 6% growth compared to the midpoint of the preliminary 2025 revenue range[53] - Adjusted gross margin for 2026 is projected to be between 68% and 69%[53] - Adjusted EBITDA for 2026 is expected to be between $37 million and $49 million, representing approximately 43% growth over the midpoint of the previous full year 2025 guidance range[53] - The company is targeting high single-digit to low double-digit percentage annual revenue growth in the long term[60] Strategic Focus and Market Expansion - The company is prioritizing the Cancer Care Continuum to drive accelerated growth and profitability[11, 60] - The company plans to leverage market-leading positions and new products to accelerate growth in markets such as Hereditary Cancer Testing (HCT), therapy selection, prostate cancer, and molecular residual disease (MRD)[13] - The total addressable market (TAM) for therapy selection, HRD (Homologous Recombination Deficiency) & CGP (Comprehensive Genomic Profiling) is estimated at $8 billion, with an estimated annual market growth of 14-17%[13] - The MRD market has a TAM of $21 billion with an estimated annual market growth of 15-20%[13] - The company is expanding its testing menu to serve more of the Cancer Care Continuum, including hereditary cancer screening, diagnosis & therapy selection, and molecular residual disease monitoring[15, 16]

Financial Projections - Myriad Genetics, Inc. expects fourth quarter total revenues to be between $207 million and $209 million [1] - For the full year 2025, total revenues are projected to be between $822 million and $824 million [1] - For the full year 2026, the company projects revenue in a range of $860 million to $880 million and adjusted EBITDA in a range of $37 million to $49 million [1] Earnings Call - The company plans to release its actual financial results for the fourth quarter during its earnings call scheduled for February 2026 [1]

Testing Volume Projections - Myriad Genetics, Inc. expects total test volumes in 2025 to be approximately 1.5 million, reflecting a 1% year-over-year increase[4] - The company anticipates a 7% year-over-year growth in hereditary cancer testing volume for 2025[4] - Mental health testing volume is projected to grow by approximately 6% year-over-year in 2025[4] - Prenatal health testing volume is expected to decrease by approximately 4% year-over-year in 2025[4] Financial Guidance - Myriad Genetics, Inc. introduced full year 2026 financial guidance alongside the preliminary revenue announcement[4]

Core Viewpoint - Myriad Genetics, Inc. has announced preliminary financial results for Q4 and full year 2025, along with financial guidance for 2026, indicating growth expectations in revenue and adjusted EBITDA [1][6]. Financial Results - The company anticipates total revenues for Q4 2025 to be between $207 million and $209 million [7]. - For the full year 2025, total revenues are expected to be between $822 million and $824 million [7]. - The preliminary results are subject to finalization and external audit, meaning they may change before the official earnings call in February 2026 [4]. 2026 Financial Guidance - Myriad Genetics projects 2026 revenue guidance to be between $860 million and $880 million, reflecting an approximate 6% increase compared to the mid-point of the preliminary 2025 revenue range [6]. - The adjusted gross margin for 2026 is expected to be between 68% and 69%, incorporating impacts from new product launches [6]. - Adjusted EBITDA for 2026 is projected to be between $37 million and $49 million, indicating an expected growth of approximately 43% over the mid-point of the previous full year 2025 guidance range [6].

Core Viewpoint - Myriad Genetics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in molecular diagnostic testing and precision medicine [1] Company Overview - Myriad Genetics is a leading company in molecular diagnostic testing and precision medicine, focused on improving health and well-being [2] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to enhance patient care and reduce healthcare costs [2]

Core Insights - Myriad Genetics, Inc. (MYGN) is positioned for growth due to a strong pipeline of product launches and a refreshed long-term strategy focused on the Cancer Care Continuum (CCC) market [2][6] - The company faces revenue challenges from the end of UnitedHealthcare's coverage for GeneSight and broader macroeconomic issues [2][11][12] Financial Performance - MYGN's shares have decreased by 53.7% over the past year, contrasting with a 19.1% growth in the industry and the S&P 500 [3] - The company's market capitalization stands at $604.3 million, with an earnings yield of 0.2%, outperforming the industry's -29.4% yield [3] Product Development - Myriad Genetics is actively launching new products, including the Prequel Prenatal Screen and the Foresight Carrier Screening test, which enhance its testing portfolio [4] - The upcoming launch of the expanded MyRisk with RiskScore panel is anticipated to drive growth in the $6 billion market [5] Strategic Focus - The company's renewed strategy emphasizes growth in the CCC market, aiming to increase volumes of the MyRisk hereditary cancer test and expand into high-growth segments like therapy selection and minimal residual disease (MRD) [6][9] - Partnerships, such as with SOPHiA GENETICS, are aimed at enhancing biomarker validation and development services [6] Solvency and Financial Health - Myriad Genetics reported cash and cash equivalents of $145.4 million with no current debt, indicating strong solvency [10] Revenue Challenges - The termination of GeneSight coverage by UnitedHealthcare is expected to negatively impact MYGN's revenues and profitability [11] - Macroeconomic factors, including inflation and rising costs from U.S. tariffs, are anticipated to pressure the company's bottom line [12] Revenue Estimates - The Zacks Consensus Estimate for MYGN's 2025 revenues is projected at $821.5 million, reflecting a 1.9% decline from the previous year [13]